Results 181 to 190 of about 18,827 (200)

Synthesis and Clinical Development of Palbociclib: An Overview

Medicinal Chemistry, 2022
Subhabrata Kar, Saurabh Maru
exaly  

Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway

European Journal of Cancer, 2021
Huan Yu, Jie Dai, Xuan Wang
exaly  

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of Oncology, 2018
Paul Cottu, David Gentien, Jean-Sébastien Frenel   +2 more
exaly  

Physiologically Based Pharmacokinetic Modeling of Palbociclib

Journal of Clinical Pharmacology, 2017
Yanke Yu
exaly  

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Annals of Oncology, 2018
Antonio Bernardo, Luca Malorni, Chiara Biagioni   +2 more
exaly  

Palbociclib

Reactions Weekly, 2015
openaire   +1 more source

P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy

Cancer Letters, 2019
Sebastiã Sabater, Ricardo Sanchez-Prieto, Olga Roche   +2 more
exaly  

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of Oncology, 2018
Hope Rugo, Miguel Martin, H Bhattacharyya   +2 more
exaly  

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Molecular Oncology, 2017
Kuen-Feng Chen
exaly  

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

European Journal of Cancer, 2017
Joelle Helou, K I Pritchard
exaly